Literature DB >> 1431137

Priming of human eosinophils by platelet-activating factor enhances the number of cells able to bind and respond to opsonized particles.

M Blom1, A T Tool, D Roos, A J Verhoeven.   

Abstract

Addition of platelet-activating factor (PAF) to human eosinophils leads to the modulation of eosinophil responses. Earlier work from our laboratory has shown that the respiratory burst and homotypic aggregation response in these cells induced by opsonized particles (serum-treated zymosan, STZ), is strongly enhanced after pretreatment (priming) with PAF. In the present study we have investigated the effect of PAF on the binding of fluorescent STZ particles to human eosinophils. Addition of STZ to eosinophils isolated from the peripheral blood of normal donors results in an interaction of the STZ particles with only 30 to 40% of the cells. Treatment of the eosinophils with PAF (1 microM) for 2 min strongly enhanced the rate of particle binding and also doubled the percentage of eosinophils binding STZ. The effect of PAF priming is most likely mediated by a change in CR3, because it is reversed by mAb B2.12 blocking the iC3b binding site of CR3 and unaffected by mAb IV.3 blocking Fc gamma RII. This change is not an increase in cell surface expression of CR3, and it requires an active cellular metabolism to be maintained. The functional consequences of the effect of PAF on STZ binding were investigated in the nitro-blue tetrazolium dye slide test. PAF priming strongly enhanced the percentage of eosinophils producing oxygen radicals after STZ stimulation. Our findings indicate that the priming phenomenon observed in human eosinophils consists, at least in part, of a recruitment of cells able to interact with and to respond to opsonized particles.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1431137

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Phospholipase D-derived phosphatidic acid is involved in the activation of the CD11b/CD18 integrin in human eosinophils.

Authors:  A T Tool; M Blom; D Roos; A J Verhoeven
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

2.  Leukocyte adhesion deficiency type 1 (LAD-1)/variant. A novel immunodeficiency syndrome characterized by dysfunctional beta2 integrins.

Authors:  T W Kuijpers; R A Van Lier; D Hamann; M de Boer; L Y Thung; R S Weening; A J Verhoeven; D Roos
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

3.  Priming effect of platelet activating factor on leukotriene C4 from stimulated eosinophils of asthmatic patients.

Authors:  K Shindo; K Koide; Y Hirai; M Sumitomo; M Fukumura
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

4.  Bactericidal activity of human eosinophilic granulocytes against Escherichia coli.

Authors:  T Persson; P Andersson; M Bodelsson; M Laurell; J Malm; A Egesten
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

5.  Eosinophil-Cryptococcus neoformans interactions in vivo and in vitro.

Authors:  M Feldmesser; A Casadevall; Y Kress; G Spira; A Orlofsky
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

6.  Differential effects of the PAF receptor antagonist UK-74,505 on neutrophil and eosinophil accumulation in guinea-pig skin.

Authors:  M J Sanz; V B Weg; D T Walsh; T J Williams; S Nourshargh
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.